Prognosis of patients with heart failure and reduced ejection fraction in China

Xu,Yu; Shi,Yanan; Zhu,Zhongyu; Cui,Changhe; Li,Bei; Chen,Fang; Li,Dan; Chen,Songhu; Guo,Yang

doi:10.3892/etm.2013.1341

Prognosis of patients with heart failure and reduced ejection fraction in China

Authors:
- Yu Xu
- Yanan Shi
- Zhongyu Zhu
- Changhe Cui
- Bei Li
- Fang Chen
- Dan Li
- Songhu Chen
- Yang Guo
View Affiliations

Affiliations: Department of Cardiology, Henan Province People's Hospital, The People's Hospital of Zhengzhou University, Zhengzhou, Henan 450003, P.R. China
Published online on: October 11, 2013 https://doi.org/10.3892/etm.2013.1341
Pages: 1437-1442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the 5‑year survival and medication status of patients with chronic heart failure (HF) and reduced ejection fraction (HFrEF) in China. This study is a single-center, retrospective study and patients with HF and a left ventricular ejection fraction (LVEF) of ≤45%, were consecutively enrolled. The study population of 685 patients was divided into two groups, namely, LVEF ≤35 (n=371) and LVEF 36‑45% (n=314). The patients were followed up for a median of 31 months (range, 8‑61 months) and during this period, 24% of patients receiving angiotension‑converting enzyme inhibitor/angiotensin receptor blocker (ACEI/ARB) treatment and 23% of those receiving β‑blockers reached the maximum tolerated dose. Of the 191 total mortalities (28%), 127 were due to pump failure (19%) and 42 (6%) were sudden deaths. A Cox proportional hazards regression model was used to identify the variables associated with the risk of mortality. Kaplan‑Meier curves and log‑rank tests were used to compare the survival times of patients in the LVEF ≤35% and LVEF of 36‑45% groups. The predictors of all-cause mortality were advanced age, body mass index, New York Heart Association functional class and lack of oral β‑blockers at discharge. Patients with HFrEF have poor prognoses in China, particularly those patients with an LVEF of ≤35%. Therefore, cardiologists should strive to improve the prognosis of HF among Chinese patients and focus on the importance of the practical application of HF diagnosis and treatment guidelines.

View Figures

View References

1	Rosamond W, Flegal K, Friday G, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics - 2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 115:e69–e171. 2007. View Article : Google Scholar : PubMed/NCBI
2	Mendez GF and Cowie MR: The epidemiological features of heart failure in developing countries: a review of the literature. Int J Cardiol. 80:213–219. 2001. View Article : Google Scholar : PubMed/NCBI
3	World Health Organization. Cardiovascular disease: prevention and control (EB/OL). http://www.who.int/dietphysicalactivity/publications/facts/cvd/en/uri. Accessed March 07, 2010
4	Cheng Z, Zhu K, Chen T, et al: Poor prognosis in chronic heart failure patients with reduced ejection fraction in China. Congest Heart Fail. 18:165–172. 2012. View Article : Google Scholar : PubMed/NCBI
5	McKee PA, Castelli WP, McNamara PM and Kannel WB: The natural history of congestive heart failure: the Framingham study. N Engl J Med. 285:1441–1446. 1971. View Article : Google Scholar : PubMed/NCBI
6	National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 39(2 Suppl 1): S1–S266. 2002.PubMed/NCBI
7	Zhou B; Cooperative Meta-Analysis Group of China Obesity Task Force. Predictive values of body mass index and waist circumference to risk factors of related diseases in Chinese adult population. Chinese Journal of Epidemiology. 23:5–10. 2002.(In Chinese).
8	Dickstein K, Cohen-Solal A, Filippatos G, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail. 10:933–989. 2008.
9	Kawashiro N, Kasanuki H, Ogawa H, Matsuda N and Hagiwara N; Heart Institute of Japan - Department of Cardiology (HIJC) Investigators. Clinical characteristics and outcome of hospitalized patients with congestive heart failure: results of the HIJC-HF registry. Circ J. 72:2015–2020. 2008. View Article : Google Scholar : PubMed/NCBI
10	Cowie MR, Wood DA, Coats AJ, et al: Survival of patients with a new diagnosis of heart failure: a population based study. Heart. 83:505–510. 2000. View Article : Google Scholar : PubMed/NCBI
11	Stewart S, MacIntyre K, Hole DJ, Capewell S and McMurray JJ: More ‘malignant’ than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail. 3:315–322. 2001.
12	Ho KK, Anderson KM, Kannel WB, Grossman W and Levy D: Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 88:107–115. 1993. View Article : Google Scholar : PubMed/NCBI
13	Senni M, Tribouilloy CM, Rodeheffer RJ, et al: Congestive heart failure in the community: trends in incidence and survival in a 10-year period. Arch Intern Med. 159:29–34. 1999.PubMed/NCBI
14	Levy WC, Mozaffarian D, Linker DT, et al: The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 113:1424–1433. 2006. View Article : Google Scholar : PubMed/NCBI
15	McDonagh TA, Cunninghanl AD, Morrison CE, et al: Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population. Heart. 86:21–26. 2001. View Article : Google Scholar : PubMed/NCBI
16	Hartmann F, Packer M, Coats AJ, et al: Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation. 110:1780–1786. 2004. View Article : Google Scholar
17	Doust JA, Pietrzak E, Dobson A and Glasziou P: How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ. 330:6252005. View Article : Google Scholar : PubMed/NCBI
18	Zamora E, Lupón J, de Antonio M, et al: The obesity paradox in heart failure: Is etiology a key factor? Int J Cardiol. 166:601–605. 2013. View Article : Google Scholar : PubMed/NCBI
19	No authors listed. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 353:2001–2007. 1999. View Article : Google Scholar
20	No authors listed. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomized trial. Lancet. 353:9–13. 1999. View Article : Google Scholar : PubMed/NCBI
21	Packer M, Fowler M, Rouleau J, et al: COPERNICUS (carvedilol prospective randomized cumulative survival trial): A multicenter randomized double-blind placebo-controlled study to determine the effect of carvedilol on mortality in severe congestive heart failure. Cardiovasc Drugs Ther. 13:241999.
22	Society of Cardiology, Chinese Medical Association. Retrospective investigation of hospitalized patients with heart failure in some parts of China in 1980, 1990 and 2000. Chinese Journal of Cardiology. 30:450–454. 2002.(In Chinese).
23	Cao YM, Hu DY, Wang HY and Wu Y: A survey of medical therapies for chronic heart failure in primary hospitals in China. Chinese Journal of Internal Medicine. 45:907–909. 2006.(In Chinese).